Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Suicidality

Psilocybin for Suicidality

48 papers and 5 clinical trials exploring psilocybin as a treatment for suicidality.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationMore than 727,000 deaths by suicide worldwide each year

Suicidality

Suicidality covers the spectrum of suicidal thoughts, plans and behaviours, and it contributes to more than 727,000 deaths worldwide each year. The strongest evidence for rapidly reducing suicidal thinking is for ketamine and esketamine, and esketamine carries a specific regulatory approval. But even there, a reduction in suicide itself has not been proven, and classic psychedelics remain unproven for suicidality and can carry real risks for people in crisis. This is a research summary, not medical advice.

Full Suicidality profile

Academic Research

48 papers
Paywallindividual

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial

This open-label single-arm trial (n=20) found that a single 25 mg dose of psilocybin with psychological support was linked to rapid and lasting reductions in chronic suicidal thoughts and depression over 12 weeks. No serious adverse events were reported.

Published
May 13, 2026
Journal
Journal of Clinical Psychiatry
Authors
Vaart, A. V. D., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A., Aaronson, S. T.
Open Accessindividual

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

In this triple‑blind, active placebo‑controlled randomised trial (n=144) of adults with treatment‑resistant depression, two 25 mg doses of psilocybin plus adjunct psychotherapy produced clinically meaningful reductions in depressive symptoms on exploratory secondary measures but did not significantly improve the pre‑second‑dose HAMD17 response rate versus nicotinamide.

Published
March 18, 2026
Journal
JAMA Psychiatry
Authors
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Kirchen, N., Kulakova, E., Kunz, L., Meijer, A., Rohrmoser, B., Wellek, S., Berger, M. M., Gründer, G.
Paywallindividual

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

This randomised clinical trial (n=15) found that psilocybin (up to 21mg/70kg) given over up to eight weekly sessions was well-tolerated with no serious adverse events, and significantly reduced OCD symptoms compared to placebo, with 73% of participants responding and 40% reaching remission by the end of the 8-week treatment, with meaningful effects still present at 6 months.

Published
March 13, 2026
Journal
Journal of Psychopharmacology
Authors
Moreno, F. A., Allen, K. E., Wiegand, C. B., Dunne, R., Prickett, J. I., Bayze, B., Allen, J. J. B.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

In a single‑arm, open‑label pilot of 15 people with methamphetamine use disorder, outpatient psilocybin‑assisted psychotherapy (single 25 mg oral dose with preparatory and integration sessions) was feasible and well tolerated with no serious adverse events, and was associated with reductions in self‑reported methamphetamine use and craving at 28 and 90 days; a larger randomised trial is required to confirm efficacy and safety.

Published
September 20, 2025
Journal
Addiction
Authors
Knock, E., Siefried, K. J., Gill Bedi, |., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., Brett, J., Bedi, G.
Open Accessindividual

Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial

This randomised controlled trial in 25 frontline physicians and nurses found that adding group psilocybin‑assisted psychotherapy (25 mg) to an 8‑week MBSR curriculum produced larger reductions in depressive symptoms at two weeks and greater improvements on burnout subscales, demoralisation and connectedness than MBSR alone. The intervention was well tolerated (only grade 1–2 adverse events, no serious AEs), suggesting that combining psilocybin with mindfulness training may be a promising treatment for COVID‑19‑related depression and burnout in healthcare providers.

Published
September 19, 2025
Journal
PLOS Medicine
Authors
Lewis, B. R., Hendrick, J., Byrne, K., Msph, M. O., Wu, C., Garland, E. L.

Clinical Trials

5 trials
WithdrawnPhase II

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

This Phase II, non-randomised, open-label, parallel-group trial (n=150) will study response to three neuroplasticity-enhancing interventions in civilian and Veteran adults (aged 18–69) at low, intermediate or high risk for self-harm. The study will evaluate clinical change in suicidal ideation (Scale of Suicidal Ideation from baseline to the post‑treatment visit at Month 6) and aim to characterise neurobiological and blood-based markers associated with risk and treatment response. Participants are allocated to one of three experimental arms: two sessions of fMRI neurofeedback targeting amygdala activity, an accelerated theta burst stimulation programme of 50 sessions delivered to the dorsolateral prefrontal cortex, or psilocybin‑assisted therapy comprising three preparation sessions, two psilocybin administration sessions and two integration sessions. Baseline and post‑treatment assessments include clinical measures, structural and functional MRI and blood sampling for circular RNA (circRNA); an artificial intelligence analytic team will use these multimodal data to develop predictive models of behavioural risk and treatment response.

Started
May 1, 2026
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07484906
RecruitingPhase I

PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

This triple-blind, placebo-controlled trial (n=30) will investigate the effects of a sub-hallucinogenic dose of psilocybin (5 mg) combined with Imagery Re-Scripting (ImRS) on cognitive processes and self-harm behaviour in young people aged 16–25.

Started
March 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06798636
RecruitingPhase I

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed with Advanced Stage Cancer

This open-label, Phase I trial (n=15) will assess the safety and efficacy of psilocybin (25mg) alongside psychotherapy for treating demoralization syndrome in patients with advanced-stage cancer.

Started
March 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06818994
RecruitingPhase II

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression

Non-randomised, single-group Phase II trial (n=10) assessing safety and acceptability of up to two 25 mg oral psilocybin administrations with therapeutic support in individuals with Bipolar II depression and suicidal ideation (second dose optional, 4 weeks apart).

Started
January 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06706232
CompletedPhase II

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation.

Started
January 24, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05220410

Explore further

Search all Psilocybin papers Search all Suicidality trials Full Psilocybin profile Full Suicidality profile